Superluminal Medicines Inc.
Ajay Yekkirala, PhD, is a prominent figure in the biotechnology and life sciences sectors, currently serving as Co-Founder and SVP, Head of Discovery at Superluminal Medicines Inc since July 2023. Prior experience includes roles as VP, Head of Biology at RA Capital Management, L.P., and Co-Founder & Chief Scientific Officer at Blue Therapeutics, where significant advancements in pain management and nerve regeneration were achieved. Academically, Ajay Yekkirala holds a postdoctoral fellowship in Neuroscience from Harvard Medical School and a PhD in Pharmacology from the University of Minnesota. Research expertise encompasses neuroimmunology, receptor biology, and drug discovery, evidenced by a robust publication record and innovative project leadership during tenures at prestigious institutions, including Children's Hospital Boston and Harvard Medical School.
This person is not in any teams
Superluminal Medicines Inc.
Superluminal Medicines is a Boston-based generative biology and chemistry company developing a differentiated pipeline and revolutionizing the speed and accuracy of how medicine is created. Our platform creates candidate-ready compounds with unprecedented speed using a comprehensive combination of deep biology and chemistry expertise, machine learning, and proprietary big data infrastructure. The predict-design-test architecture accurately models protein shapes and designs highly selective compounds to target the precise structural change for therapeutic effect. Our discovery engine is powered by an industry-leading, pharmacokinetic and toxicology in silico prediction capability. With a lead program candidate expected in the near term, our proprietary pipeline validates our platform with initial programs focused on high-value GPCR targets. We’re pleased to be backed by a strong network of investors including RA Capital Management, Insight Partners, NVIDIA and Gaingels.